The application for uni PTH is under approval

Liankang Biology (00690) announced that the new drug application of parathyroid hormone (1-34) isoisomer uni-pth independently developed by the group has been accepted and approved by the State Food and drug administration The application for uni-pth is in the process of approval, which is for postmenopausal women with osteoporosis According to other applications for new biological drugs, it usually takes 24 months for the State Food and drug administration to inform its approval results Once approved, Liankang bio will be approved to launch unipth in the Chinese market The group is also developing innovative preparations and drug delivery tools for uni-pth About Liankang Biotechnology Group Co., Ltd., referred to as Liankang biotechnology group (English: uni Bio Science Group) Limited, HKEx: 0690) In 1992, Tu Guihong, a former professor of Biology Department of Jinan University, and his friends established the "Guangzhou Huasheng Genetic Engineering Research Institute" (the predecessor of Shenzhen huashengyuan Genetic Engineering Development Co., Ltd.) That is to say, on December 15, 2005, the company was listed on the main board of Hong Kong Stock Exchange in exchange for new high quasi Holding Co., Ltd The chairman is Tang Jiecheng The business is mainly engaged in the research and development of innovative drugs in the biopharmaceutical industry [2], i.e "Beijing Bo Kang Gene Technology Co., Ltd." and "Dongguan Taili Bioengineering Co., Ltd." Headquartered at 13 / F, Volkswagen Bank Centre, 120 des Voeux Road Central, Hong Kong